Global R&D Pipeline
My Favorite
Hot Targets:
TSLP
Back
Total number of drugs
73
Phase II and later clinical stages
19.2%
Involving companies
111
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CXX-168 | CXX-168 | Nanobody | Immune System Diseases Respiratory Diseases | TSLP inhibitors | Hangzhou Chance Pharmaceuticals Co., Ltd. | Hangzhou Chance Pharmaceuticals Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | CXX-168 | - | - | detail > | |
| HXN-1012 | HXN-1012 | Bispecific antibody | Immune System Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | IL-13 inhibitors TSLP inhibitors | Huashen Zhiyao Technology (Beijing) Co., Ltd. | Huashen Zhiyao Technology (Beijing) Co., Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | HXN-1012 | - | - | detail > | |
| QX-031N | QX-031N | Bispecific antibody | Respiratory Diseases | IL-33 inhibitors TSLP inhibitors | Qyuns Therapeutics Co., Ltd. | Qyuns Therapeutics Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | QX-031N | - | - | detail > | |
| Bicycle 46 | Bicycle 46 | Synthetic peptide | Immune System Diseases Respiratory Diseases | TSLP inhibitors | AstraZeneca PLC | BicycleTx Ltd. AstraZeneca PLC | Preclinical | - | - | - | - | - | - | - | - | - | Bicycle 46 | - | - | detail > | |
| BD-9 | BD-9 | Bispecific antibody | Immune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | IL-13 inhibitors TSLP inhibitors Immunomodulators | Biolojic Design Ltd. | Biolojic Design Ltd. Teva Pharmaceutical Industries Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | BD-9 | - | - | detail > | |
| QLP3119 | QLP3119 | Biological products | Immune System Diseases Respiratory Diseases | IL-33 inhibitors TSLP inhibitors | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd. | IND Approval | IND Approval | - | - | - | - | - | - | - | - | QLP3119 | - | - | detail > | |
| HB0056 | HB0056 | Bispecific antibody | Immune System Diseases Respiratory Diseases | IL-11 modulators TSLP modulators | Shanghai Huaaotai Biopharmaceutical Co., Ltd. | Shanghai Huaaotai Biopharmaceutical Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | HB0056 | - | - | detail > | |
| LQ-043H | LQ-043H | Nanobody | Immune System Diseases Respiratory Diseases | TSLP modulators | Shanghai Novamab Biopharmaceuticals Co., Ltd. | Shanghai Novamab Biopharmaceuticals Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | LQ-043H | - | - | detail > | |
| HXN-1013 | HXN-1013 | Bispecific antibody | Immune System Diseases Respiratory Diseases | IL-33 inhibitors TSLP inhibitors | Huashen Zhiyao Technology (Beijing) Co., Ltd. | Huashen Zhiyao Technology (Beijing) Co., Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | HXN-1013 | - | - | detail > | |
| Anti-TSLP antibody (Perseus) | Anti-TSLP antibody (Perseus) | Monoclonal antibody | Immune System Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | TSLP inhibitors | Perseus Therapeutics, Inc. | Perseus Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Anti-TSLP antibody (Perseus) | - | - | detail > |
Total 73 data
1
2
3
4
5
6
7
8
